Funding for this research was provided by:
National Cancer Institute (R01CA198533, R01CA201246)
American Association for Cancer Research (18-40-43-LHUI)
First Online: 20 June 2019
: The authors declare that they have no competing interests related to this work. However, SD has received research support from Lytix Biopharma and Nanobiotix, as well as consultant fees from EMD Serono, Mersana Therapeutics, AbbVie Inc., AstraZeneca, Cytune Pharma, and Lytix Biopharma. SCF has received prior honoraria, for consulting or as a speaker, from AstraZeneca, Merck, Regeneron, Bayer, and EMD Serono, as well as research funding from Varian, Merck, and Bristol-Meyers Squibb.